Synthesis of Novel N 4 -Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents.
Franck AmblardJulia C LecherRamyani DeShu Ling GohChengwei LiMahesh KasthuriNicolas G BiteauLonghu ZhouZahira TberJessica A Downs-BowenKeivan ZandiRaymond F SchinaziPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N 4 -hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs.